×
Profound Medical Operating Expenses 2020-2024 | PROF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Profound Medical operating expenses from 2020 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Profound Medical Operating Expenses 2020-2024 | PROF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Profound Medical operating expenses from 2020 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.2B
Takeda Pharmaceutical (TAK)
$43.3B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.2B
Astellas Pharma (ALPMY)
$18.2B
United Therapeutics (UTHR)
$16.1B
Summit Therapeutics (SMMT)
$14.7B
Neurocrine Biosciences (NBIX)
$12.1B
Shionogi (SGIOY)
$11.9B
Catalent (CTLT)
$10.7B
Jazz Pharmaceuticals (JAZZ)
$7.1B
Madrigal Pharmaceuticals (MDGL)
$6.9B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$5.7B
Ionis Pharmaceuticals (IONS)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$5.1B
PTC Therapeutics (PTCT)
$3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Soleno Therapeutics (SLNO)
$2.2B
NewAmsterdam Pharma (NAMS)
$2.2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Evotec AG (EVO)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.8B
Xencor (XNCR)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Indivior (INDV)
$1.4B
Harrow (HROW)
$1.4B